Novartis' Kisqali CHMP Nod In Fast-Moving Market

 
• By Alexandra Shimmings

The likely upcoming EU approval of Kisqali, Novartis' answer to Pfizer's Ibrance, opens a new front in a breast cancer marketing battle that is likely to get more intense.

Breast Cancer Awareness: Microscopic image (photomicrograph) of core biopsy for infiltrating (invasive) ductal carcinoma, detected by screening mammogram. H & E stain.
• Source: Shutterstock

More from New Products

More from Scrip